中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
12期
1271-1274
,共4页
武艳强%袁芳%冯强%李鹤飞%朱琳%侯爱军%申玉良
武豔彊%袁芳%馮彊%李鶴飛%硃琳%侯愛軍%申玉良
무염강%원방%풍강%리학비%주림%후애군%신옥량
心肌梗死%经皮冠状动脉介入治疗%腺苷%替罗非班
心肌梗死%經皮冠狀動脈介入治療%腺苷%替囉非班
심기경사%경피관상동맥개입치료%선감%체라비반
Myocardial infarction%Percutaneous coronary intervention%Adenosine%Tirofiban
目的 探讨急性ST段抬高心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)中冠状动脉内替罗非班联合高剂量腺苷的治疗效果.方法 采用前瞻性、双盲、随机研究,根据随机数字表将接受PCI的88例STEMI患者分为观察组(44例)和对照组(44例).两组均将10μg/kg替罗非班经抽吸导管于罪犯病变远端推注3 min,同时持续静脉滴注0.15 μg/(kg· min) 24 h.在此基础上,观察组患者的冠状动脉内推注腺苷(2mg,10 ml0.9%氯化钠)2次,对照组推注10 ml 0.9%氯化钠2次.评估术后两组患者的冠状动脉造影、心电图指标,随访术后患者的心肌Blush分级(MBG)、心肌梗死溶栓试验(TIMI)血流分级、校正的TIMI帧数(CTFC)、总ST段抬高回落(STR)、12个月主要不良心脏事件 (MACE)、腺苷引发的不良反应.结果 两组患者的术后TIMI血流分级、ST抬高完全回落比例比较差异均无统计学意义(P均>0.05);观察组CTFC[(21.9±3.7)帧与(24.4±4.9)帧,t=2.701,P<0.01]、MBG 3级的例数分布(24/44与14/44,x2=4.632、P<0.05)与对照组比较差异均有统计学意义.两组患者随访1、12个月时的死亡人数、MACE、靶血管血运重建以及NYHA分级比较差异均无统计学意义(P均>0.05);观察组的血压下降≥10mm Hg(15.9%与2.3%,x2=4.950,P=0.026)、新发二度以及以上房室传导阻滞(20.5%与15.9%,x2=7.221,P=0.007)的比例显著高于对照组,差异均有统计学意义;腺苷引发的不良反应均为一过性.结论 在STEMI患者治疗中,冠状动脉内替罗非班联合高剂量腺苷的应用对其PCI术后的心肌灌注有改善作用.
目的 探討急性ST段抬高心肌梗死(STEMI)患者直接經皮冠狀動脈介入治療(PCI)中冠狀動脈內替囉非班聯閤高劑量腺苷的治療效果.方法 採用前瞻性、雙盲、隨機研究,根據隨機數字錶將接受PCI的88例STEMI患者分為觀察組(44例)和對照組(44例).兩組均將10μg/kg替囉非班經抽吸導管于罪犯病變遠耑推註3 min,同時持續靜脈滴註0.15 μg/(kg· min) 24 h.在此基礎上,觀察組患者的冠狀動脈內推註腺苷(2mg,10 ml0.9%氯化鈉)2次,對照組推註10 ml 0.9%氯化鈉2次.評估術後兩組患者的冠狀動脈造影、心電圖指標,隨訪術後患者的心肌Blush分級(MBG)、心肌梗死溶栓試驗(TIMI)血流分級、校正的TIMI幀數(CTFC)、總ST段抬高迴落(STR)、12箇月主要不良心髒事件 (MACE)、腺苷引髮的不良反應.結果 兩組患者的術後TIMI血流分級、ST抬高完全迴落比例比較差異均無統計學意義(P均>0.05);觀察組CTFC[(21.9±3.7)幀與(24.4±4.9)幀,t=2.701,P<0.01]、MBG 3級的例數分佈(24/44與14/44,x2=4.632、P<0.05)與對照組比較差異均有統計學意義.兩組患者隨訪1、12箇月時的死亡人數、MACE、靶血管血運重建以及NYHA分級比較差異均無統計學意義(P均>0.05);觀察組的血壓下降≥10mm Hg(15.9%與2.3%,x2=4.950,P=0.026)、新髮二度以及以上房室傳導阻滯(20.5%與15.9%,x2=7.221,P=0.007)的比例顯著高于對照組,差異均有統計學意義;腺苷引髮的不良反應均為一過性.結論 在STEMI患者治療中,冠狀動脈內替囉非班聯閤高劑量腺苷的應用對其PCI術後的心肌灌註有改善作用.
목적 탐토급성ST단태고심기경사(STEMI)환자직접경피관상동맥개입치료(PCI)중관상동맥내체라비반연합고제량선감적치료효과.방법 채용전첨성、쌍맹、수궤연구,근거수궤수자표장접수PCI적88례STEMI환자분위관찰조(44례)화대조조(44례).량조균장10μg/kg체라비반경추흡도관우죄범병변원단추주3 min,동시지속정맥적주0.15 μg/(kg· min) 24 h.재차기출상,관찰조환자적관상동맥내추주선감(2mg,10 ml0.9%록화납)2차,대조조추주10 ml 0.9%록화납2차.평고술후량조환자적관상동맥조영、심전도지표,수방술후환자적심기Blush분급(MBG)、심기경사용전시험(TIMI)혈류분급、교정적TIMI정수(CTFC)、총ST단태고회락(STR)、12개월주요불양심장사건 (MACE)、선감인발적불량반응.결과 량조환자적술후TIMI혈류분급、ST태고완전회락비례비교차이균무통계학의의(P균>0.05);관찰조CTFC[(21.9±3.7)정여(24.4±4.9)정,t=2.701,P<0.01]、MBG 3급적례수분포(24/44여14/44,x2=4.632、P<0.05)여대조조비교차이균유통계학의의.량조환자수방1、12개월시적사망인수、MACE、파혈관혈운중건이급NYHA분급비교차이균무통계학의의(P균>0.05);관찰조적혈압하강≥10mm Hg(15.9%여2.3%,x2=4.950,P=0.026)、신발이도이급이상방실전도조체(20.5%여15.9%,x2=7.221,P=0.007)적비례현저고우대조조,차이균유통계학의의;선감인발적불량반응균위일과성.결론 재STEMI환자치료중,관상동맥내체라비반연합고제량선감적응용대기PCI술후적심기관주유개선작용.
Objective To compare the egicacy and security of intracoronary administration of tirofiban combined high-dose adenosine during percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (STEMI).Methods Eighty-eight cases with STEMI were randomly divided into observation group(44 cases) who were accepted 2 times intracoronary adenosine(2 mg,10 ml 0.9% NaCl),and control group(44 cases) who were afforded only 10 ml 0.9% NaCl by prospective,double-blind,and random study.The two groups were received10 g/kg tirofiban after aspiration catheter in the culprit lesion distal bolus injection of 3 rain,at the same time,continuous infusion of 0.15 g/(kg · min) for 24 h.The postoperative coronary arteriography and electrocardiogram were evaluated.Meanwhile,the postoperative myocardial blush grade(MBG),thrombolysis in myocardial infarction (TIMI),corrected TIMI frame counts (CTFC),ST-segment elevation resolution (STR) major adverse cardiac events (MACE),and adverse reactions of adenosine were recorded.Results There was no significant difference in terms of postoperative TIMI and STR between two groups (P > 0.05).The CTFC of observation group was (24.4 ± 4.9) frames,significant better than that of control group((21.9 ±3.7) frames;t =2.701,P <0.01).The ratio of MBG in observation group was 24/44,higher than that of control group(14/44 ; x2 =4.632,P < 0.05).There were no significant difference regarding of the ratio of death,MACE,target vessel revascularization,grade of NYHA between observation and control group at followed up for 1 and 12 month (P > 0.05).The ratio of patients with blood pressure decrease ≥ 10 mm Hg,new second degree atrioventricular block in observation group were 15.9% and 20.5%,higher than that in control group (2.3% and 15.9% ; x2 =4.950,7.221 ; P =0.026,0.007).The adverse reaction was transient.Conclusion The intracoronary administration of tirofiban combined high-dose adenosine during PCI in patients with STEMI plays an effective role on improvement of myocardial perfusion.